Understand the source comparison
VIP vs Other Peptides: What Makes VIP Unique
VIP operates through a fundamentally different mechanism than GLP-1 receptor agonists like semaglutide or tirzepatide. While GLP-1 agonists primarily target metabolic pathways (insulin secretion, gastric emptying, appetite suppression), what VIP actually does
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- VIP operates through a fundamentally different mechanism than GLP-1 receptor agonists like semaglutide or tirzepatide. While GLP-1 agonists primarily target metabolic pathways (insulin secretion, gastric emptying, appetite suppression), what VIP actually does is regulate smooth muscle tone and immune modulation through cAMP elevation. VIP does not significantly affect blood glucose or body weight in healthy subjects. Its therapeutic potential lies in conditions where vasodilation or immune downregulation is the primary goal. A Phase 2 trial published in The Lancet Respiratory Medicine found that inhaled aviptadil (a synthetic VIP analog) improved oxygenation in acute respiratory distress syndrome by reducing pulmonary vasoconstriction and inflammatory cytokine release.
- The comparison between VIP and BPC-157 (another widely researched peptide) highlights the specificity required when evaluating what peptides actually do. BPC-157 promotes angiogenesis and tissue repair through vascular endothelial growth factor (VEGF) upregulation, whereas VIP directly relaxes existing smooth muscle without stimulating new vessel formation. For research models investigating pulmonary hypertension, VIP analogs demonstrate superior efficacy in reducing pulmonary arterial pressure compared to non-vasodilatory peptides.
- At Real Peptides, every batch of VIP undergoes HPLC verification to confirm >98% purity and correct amino acid sequencing. What VIP actually does in a research protocol is only as reliable as the peptide's structural integrity. Even minor contamination with truncated peptide fragments can skew receptor binding affinity by 30–50%. This is why sourcing matters more for short-half-life peptides like VIP than for more stable compounds like BPC-157 or TB-500.